| アブストラクト | INTRODUCTION: Patient reporting in pharmacovigilance is important and contributes to signal detection. However, descriptions of methodologies for using patient reports in signal detection are scarce, and published experiences of how patient reports are used in pharmacovigilance are limited to a few individual countries. OBJECTIVE: Our objective was to explore the contribution of patient reports to global signal detection in VigiBase. METHODS: Data were retrieved from VigiBase in September 2016. Drug-event-combination series were restricted to those with >50% patient reports, defined as reporter type "Consumer/non-health professional" per E2B reporting standard. vigiRank was applied to patient reports to prioritize combinations for assessment. Product information for healthcare professionals (HCPs) as well as patient information leaflets (PILs) were used as reference for information on adverse drug reactions (ADRs). Staff from the Uppsala Monitoring Centre and the Netherlands Pharmacovigilance Centre Lareb categorized the combinations. Potential signals proceeded to a more in-depth clinical review to determine whether the safety concern should be communicated as a "signal." RESULTS: Of the 212 combinations assessed, 20 (9%) resulted in eight signals communicated within the World Health Organization (WHO) programme for international drug monitoring. Review of PILs revealed insufficient ADR descriptions for patients and examples of poor consistency with product information for HCPs. Patient narratives provided details regarding the experience and impact of ADRs and evidence that patients make causality and personal risk assessments. CONCLUSIONS: Safety concerns described in patient reports can be identified in a global database including previously unknown ADRs as well as new aspects of known ADRs. Patient reports provide unique information valuable in signal assessment and should be included in signal detection. Novel approaches to highlighting patient reports in statistical signal detection can further improve the contribution of patient reports to pharmacovigilance. |
|---|
| ジャーナル名 | Drug safety |
|---|
| Pubmed追加日 | 2017/9/22 |
|---|
| 投稿者 | Watson, Sarah; Chandler, Rebecca E; Taavola, Henric; Harmark, Linda; Grundmark, Birgitta; Zekarias, Alem; Star, Kristina; van Hunsel, Florence |
|---|
| 組織名 | Uppsala Monitoring Centre, Uppsala, Sweden. sarah.watson@who-umc.org.;Uppsala Monitoring Centre, Uppsala, Sweden.;Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands.;Department of Surgery, Uppsala University, Uppsala, Sweden.;Department of Public Health and Caring Sciences, Uppsala University, Uppsala,;Sweden. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/28933055/ |
|---|
